This press release contains certain forward-looking statements about prasugrel for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndromes who are managed with percutaneous coronary intervention and reflects Daiichi Sankyo's and Lilly's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that future study results and patient experience will be consistent with study findings to date or that the product will be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filing with the United States Securities and Exchange Commission and Daiichi Sankyo's filings with the Tokyo Stock Exchange. Daiichi Sankyo and Lilly undertake no duty to update forward-looking statements.
Efient(R) is a registered trademark of Eli Lilly and Company.
(1) The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Guidelines on myocardial revascularization. European Heart Journal. Published online 29 August 2010. Doi:10.1093/eurheartj/ehq277.
(2) Wiviott SD, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel - Thrombolysis in Myocardial Infarction 38. Circulation 2008; 118: 1626-1636.
(3) British Heart Foundation Health Promotion Research Group. European Cardiovascular Disease Statistics 2008 (http://www.heartstats.org/temp/esspweb08...). Accessed 5 March 2010.
(4) American Heart Association. Heart Disease and Stroke Statistics - 2008 Update (http://www.americanheart.org/downloadabl...). Accessed 5 March 2010.
(5) WebMD Medical Reference in Collaboration with the Cleveland Clinic. Heart Disease: Coronary Artery Disease (http://www.webmd.com/heart-disease/guide/heart-disease-coron...). Accessed 5 March 2010.
(Logo: http://photos.prnewswire.com/prnh/20090922/DE78874LOGO-b )
(Logo: http://www.newscom.com/cgi-bin/prnh/20090922/DE78874LOGO-b )
Tamara Hull, Eli Lilly and Company, +1-317-651-9116 (office), +1-317-614-5132 (cell); or Dr. Michaela Paudler-Debus, Daiichi Sankyo Europe GmbH, +49-(0)89-78-08-685 (office), +49-(0)172-845-8974 (cell); or Shigemichi Kondo, Daiichi Sankyo (Tokyo), +81-3-6225-1126 (office)